4 Biotechnology Stocks to Sell Now

IMGN, PGNX, BTX, YMI slump in weekly rankings

By Portfolio Grader


The ratings of four Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Immunogen Inc.‘s (NASDAQ:IMGN) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Immunogen develops pharmaceuticals, primarily for the treatment of cancer. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity, and Sales Growth, IMGN also gets an F. To get an in-depth look at IMGN, get Portfolio Grader’s complete analysis of IMGN stock.

Progenics Pharmaceuticals (NASDAQ:PGNX) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock price has fallen 14.8% over the past month, worse than the 2.4% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Slipping from a C to a D rating, BioTime (AMEX:BTX) takes a hit this week. BioTime is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The stock gets F’s in Equity and Cash Flow. As of Oct. 17, 2012, 12.4% of outstanding BioTime shares were held short. The price of BTX fell 5.7% over the past month. For a full analysis of BTX stock, visit Portfolio Grader.

YM BioSciences (AMEX:YMI) experiences a ratings drop this week, going from last week’s C to a D. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. The stock also gets an F in Equity. Over the last month, shares of the company declined 19.8%. For more information, get Portfolio Grader’s complete analysis of YMI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

Article printed from InvestorPlace Media, https://investorplace.com/2012/10/4-biotechnology-stocks-to-sell-now-imgn-pgnx-btx/.

©2018 InvestorPlace Media, LLC